Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaJournal of clinical oncology, 2022-01, Vol.40 (2), p.127-137 [Peer Reviewed Journal]2021 by American Society of Clinical Oncology 2021 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.21.02229 ;PMID: 34818112Full text available |
|
2 |
Material Type: Article
|
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaJournal of clinical oncology, 2015-09, Vol.33 (25), p.2780-2788 [Peer Reviewed Journal]2015 by American Society of Clinical Oncology. ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2014.58.3377 ;PMID: 26014293Full text available |
|
3 |
Material Type: Article
|
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive MelanomaJournal of clinical oncology, 2013-12, Vol.31 (34), p.4311-4318 [Peer Reviewed Journal]2015 INIST-CNRS ;2013 by American Society of Clinical Oncology 2013 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2013.51.4802 ;PMID: 24145345Full text available |
|
4 |
Material Type: Article
|
Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell CarcinomasJournal of clinical oncology, 2020-09, Vol.38 (26), p.3051-3061 [Peer Reviewed Journal]Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.19.03357 ;PMID: 32730186Full text available |
|
5 |
Material Type: Article
|
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialThe lancet oncology, 2021-05, Vol.22 (5), p.643-654 [Peer Reviewed Journal]2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;COPYRIGHT 2021 Elsevier B.V. ;2021. Elsevier Ltd ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(21)00065-6 ;PMID: 33857412Full text available |
|
6 |
Material Type: Article
|
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaJNCI : Journal of the National Cancer Institute, 2014-09, Vol.106 (9), p.1 [Peer Reviewed Journal]The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. ;Copyright Oxford Publishing Limited(England) Sep 2014 ;The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. 2014 ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/dju246 ;PMID: 25217772 ;CODEN: JNCIEQFull text available |
|
7 |
Material Type: Article
|
A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma PatientsCancer immunology research, 2019-07, Vol.7 (7), p.1162-1174 [Peer Reviewed Journal]2019 American Association for Cancer Research. ;ISSN: 2326-6066 ;EISSN: 2326-6074 ;DOI: 10.1158/2326-6066.cir-18-0500 ;PMID: 31088844Full text available |
|
8 |
Material Type: Article
|
Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysisJournal of clinical oncology, 2015-03, Vol.33 (7), p.773-781 [Peer Reviewed Journal]2015 by American Society of Clinical Oncology. ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2014.57.4756 ;PMID: 25605840Full text available |
|
9 |
Material Type: Article
|
MelanomaThe Lancet (British edition), 2018-09, Vol.392 (10151), p.971-984 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Sep 15, 2018 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(18)31559-9 ;PMID: 30238891Full text available |
|
10 |
Material Type: Article
|
The Rapid Rise in Cutaneous Melanoma DiagnosesThe New England journal of medicine, 2021-01, Vol.384 (1), p.72-79 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMsb2019760 ;PMID: 33406334Full text available |
|
11 |
Material Type: Article
|
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated MelanomaThe New England journal of medicine, 2017-11, Vol.377 (19), p.1813-1823 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1708539 ;PMID: 28891408Full text available |
|
12 |
Material Type: Article
|
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyCancer cell, 2019-02, Vol.35 (2), p.238-255.e6 [Peer Reviewed Journal]2019 Elsevier Inc. ;Copyright © 2019 Elsevier Inc. All rights reserved. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2019.01.003 ;PMID: 30753825Full text available |
|
13 |
Material Type: Article
|
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterJournal of clinical oncology, 2015-10, Vol.33 (28), p.3193-3198 [Peer Reviewed Journal]2015 by American Society of Clinical Oncology. ;2015 by American Society of Clinical Oncology 2015 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2015.60.8448 ;PMID: 26282644Full text available |
|
14 |
Material Type: Article
|
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic MelanomaJournal of clinical oncology, 2011-04, Vol.29 (10), p.1239-1246 [Peer Reviewed Journal]2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2010.32.4327 ;PMID: 21343559Full text available |
|
15 |
Material Type: Article
|
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell TherapyCancer cell, 2017-05, Vol.31 (5), p.711-723.e4 [Peer Reviewed Journal]2017 Elsevier Inc. ;Copyright © 2017 Elsevier Inc. All rights reserved. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2017.04.003 ;PMID: 28486109Full text available |
|
16 |
Material Type: Article
|
Targeting Oncogenic Drivers and the Immune System in MelanomaJournal of clinical oncology, 2013-02, Vol.31 (4), p.499-506 [Peer Reviewed Journal]2014 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.45.5568 ;PMID: 23248252Full text available |
|
17 |
Material Type: Article
|
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialThe lancet oncology, 2012-08, Vol.13 (8), p.782-789 [Peer Reviewed Journal]Elsevier Ltd ;2012 Elsevier Ltd ;Copyright © 2012 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Aug 2012 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(12)70269-3 ;PMID: 22805292 ;CODEN: LANCAOFull text available |
|
18 |
Material Type: Article
|
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Nature medicine, 2021-02, Vol.27 (2), p.301-309 [Peer Reviewed Journal]COPYRIGHT 2021 Nature Publishing Group ;The Author(s), under exclusive licence to Springer Nature America, Inc. 2021. ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/s41591-020-01188-3 ;PMID: 33558722Full text available |
|
19 |
Material Type: Article
|
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or AmplificationJournal of clinical oncology, 2011-07, Vol.29 (21), p.2904-2909 [Peer Reviewed Journal]2015 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2010.33.9275 ;PMID: 21690468Full text available |
|
20 |
Material Type: Article
|
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysisThe lancet oncology, 2018-03, Vol.19 (3), p.310-322 [Peer Reviewed Journal]2018 Elsevier Ltd ;Copyright © 2018 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Mar 1, 2018 ;2018. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(18)30078-0 ;PMID: 29449192Full text available |